Anzeige
Mehr »
Samstag, 18.10.2025 - Börsentäglich über 12.000 News
Europa rüstet Drohnenabwehr auf - und diese Aktie könnte die Technologie dazu liefern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
344 Leser
Artikel bewerten:
(2)

Biosimilars Market to Reach $143.6 Bn, Globally, by 2031 at 24.7% CAGR: Allied Market Research

Increase in incidences of diabetes and autoimmune diseases drives the growth of the global biosimilars market.

PORTLAND, Ore., July 7, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Biosimilars Market by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.

Allied Market Research Logo

Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/162

Prime determinants of growth-

Increase in incidences of diabetes and autoimmune diseases drives the growth of the global biosimilars market. Moreover, favorable government policies and new product launches in the biosimilars industry have supplemented the growth yet more. Moreover, several growth prospects in the developed as well as developing economies have been beneficial for the key players in the industry.

Covid-19 scenario-

  • The COVID-19 pandemic created difficulties for the pharmaceutical industry to focus on R&D activities including biosimilar development, which impacted the global biosimilars market negatively.
  • Moreover, there was a delay in product approvals and product launches, owing to the global health crisis, which further restricted the expansion of the market.

The oncology diseases segment to dominate by 2031-

Based on application, the oncology diseases segment accounted for more than two-fifths of the global biosimilars market share in 2021, and is anticipated to rule the roost by 2031. The same segment would also cite the fastest CAGR of 26.0% throughout the forecast period, due to rise in prevalence of cancer and increase in demand for cost-effective cancer treatment.

Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/162?reqfor=covid

The monoclonal antibodies segment to maintain the lion's share-

Based on type, the monoclonal antibodies segment held more than one-fourth of the global biosimilars market revenue in 2021, and is expected to lead the trail by 2031. The same segment would also manifest the fastest CAGR of 26.7% from 2022 to 2031. This is due to increase in R&D activities to develop new biosimilars and rise in use of monoclonal antibodies for cancer treatment.

Europe garnered the major share in 2021-

Based on region, Europe held the major share in 2021, generating nearly two-fifths of the global biosimilars market. At the same time, the same region would also grow at the fastest CAGR of 25.9% by 2031. This is attributed to rise in the prevalence of cancer and increase in launches of multiple biosimilars in the region.

Key players in the industry-

  • Exxon Mobil Corporation
  • Haihang Industry Co., Ltd.
  • Kent elastomer products
  • Kuraray Co.
  • Shell,Ltd.
  • SIBUR
  • Dupont
  • The Goodyear Tire & Rubber Company

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

Cosmetic Surgery Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Medical Device Regulatory Affairs Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Indonesia Beauty Supplements Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

COPD and Asthma Devices Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

US Fundus Camera Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Pharmaceutical Glycerine Based Products Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Plant Tissue Culture Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Medical Cannabis Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Cold Plasma Implant Treatment Devices Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

Urinary Incontinence Market - Global Opportunity Analysis and Industry Forecast, 2020-2028

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn:https://www.linkedin.com/showcase/life-sciences-industry-research/

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

© 2022 PR Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.